- Dec 12, 2003
Single versus double autologous stem-cell transplantation for multiple myeloma
IFM - Time Frame: October 1994 and March 1997 IFM (Intergroupe Francophone du Myelome) N Engl J Med, 2003 Dec 25 Single versus double autologous stem-cell transplantation for multiple myeloma Single versus double autologous stem-cell transplantation for multiple myeloma Click below for details: https://pubmed.ncbi.nlm.nih.gov/14695409/ https://www.nejm.org/doi/full/10.1056/nejmoa032290
105
- Dec 11, 2003
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
Multiple Myeloma (009) MM-009 NCT00056160 : Phase 3 - CC-5013 Plus Dex Versus Dex Alone in Previously Treated Subjects With Multiple Myeloma Relapsed Refractory Multiple Myeloma Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase. This was a phase 3, multicenter, double-blind, placebo-controlled
136
- Dec 10, 2003
FDA Approved for Multiple Myeloma treatment: Bortezomib (formerly PS-341)
On May 13, 2003, the U.S. Food and Drug Administration (FDA) granted accelerated approval for bortezomib (formerly PS-341), Velcade. Bortezomib (formerly PS-341), a promising new drug for the treatment of multiple myeloma, recently received accelerated approval from the U.S. Food and Drug Administration (FDA) for the therapy of patients with progressive myeloma after previous treatment. Two phase II studies of bortezomib used the same schedule of twice-weekly i.v. dosing for
121